Wegovy for Teens: What STEP TEENS Showed Parents

Your kid's pediatrician mentions Wegovy. Or your teenager saw it on TikTok and asked. Either way, you're now the parent at the kitchen table at 11 p.m. with a tab open, trying to figure out whether a weekly injection belongs anywhere near your 14-year-old.

It's a fair question, and a heavy one. The answer starts with a single trial, because for once the data is unusually clean. It's called STEP TEENS, it ran for 68 weeks, and it's why the FDA approved Wegovy (semaglutide 2.4 mg) for adolescents 12 and older with obesity back in December 2022. The headline number is large. The fine print around it matters just as much — and most of what gets shared online drops the fine print on the way to the headline.

This piece keeps both: the big number, and everything that gives it shape.

What STEP TEENS actually tested

STEP TEENS was a double-blind, randomized, placebo-controlled trial — the gold-standard design, where neither the families nor the researchers knew who got the drug. It enrolled 201 adolescents aged 12 to under 18 who had obesity, defined as a BMI at or above the 95th percentile for their age and sex. Published in the New England Journal of Medicine in 2022.

Here's how it was built:

Two details in that table do a lot of work. First, the 2:1 split means more teens got the drug than the placebo, which is standard in trials of this kind. Second — and this is the one people skip — both arms received lifestyle counseling. Nobody in this study was handed a pen and sent home. The placebo group worked on diet and activity too. That setup is what makes the comparison mean anything, and we'll come back to why.

A 90% completion rate over 68 weeks is high for a teenage population. It tells you the protocol was tolerable enough that most families stuck with it.

The 16% number, minus the spin

Here's the result that drives every headline. Over 68 weeks, the semaglutide group saw their BMI fall by 16.1% on average. The placebo group drifted the other way, by a hair: up 0.6%.

One group's BMI dropped by roughly a sixth. The other barely moved. That gap is the whole story, and it's worth getting the math exactly right.

Mean change in BMI from baseline to week 68: −16.1% with semaglutide, +0.6% with placebo. The estimated difference was 16.7 percentage points in favor of the drug (95% CI −20.3 to −13.2; P less than 0.001).

That second number — the 16.7-percentage-point gap — is the one to keep straight, because it's the one that gets garbled. The 16.1% is how much the drug group's BMI fell. The 16.7 points is the difference between the two groups once you subtract out the placebo arm. Related, but not the same, and mixing them up is how a real finding swells into an exaggerated one. Cleanly stated: teens on semaglutide saw their BMI fall about 16.7 percentage points more than teens who did the lifestyle work alone.

A second efficacy figure is worth knowing. By week 68, 73% of the semaglutide group (95 of 131) had lost at least 5% of their body weight, against 18% on placebo (11 of 62) — an odds ratio of 14.0. So the result wasn't carried by a handful of standout responders. It reached most of the group.

One caveat the headlines tend to lose: this is a 68-week snapshot, roughly 16 months. It says nothing about year three or year five, and BMI in a still-growing adolescent is a moving target by definition. A large effect, inside a defined window — both of those are true at once.

Who this trial was for

This is the part that falls off the instant a number that big starts traveling.

STEP TEENS studied adolescents with obesity — a BMI at or above the 95th percentile for age and sex. Not teenagers who are a little soft around the middle. Not kids a pediatrician would describe as "carrying some extra weight." A clinically defined category, measured against pediatric growth charts that account for the fact that a healthy 13-year-old and a healthy 17-year-old look nothing alike.

That line is the whole ballgame. A drug result in adolescents with obesity says nothing about whether the same drug belongs anywhere near a teen who isn't in that category. Stretching the 16.1% to cover "teens who want to slim down" is exactly the move this article exists to head off.

If your teen doesn't sit clearly inside that first column, the STEP TEENS data isn't really about them, and a good clinician will tell you the same. Eligibility here is a medical judgment about percentiles and overall health — not a number on a bathroom scale you can eyeball.

Lifestyle is the floor, the drug is the add-on

Now back to the detail from the trial design. Both groups got lifestyle counseling. So what the trial really compared was semaglutide plus lifestyle against lifestyle alone.

That comparison shaped the official conclusion, and the wording is precise:

Once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a greater reduction in BMI than lifestyle intervention alone in adolescents with obesity.

Read that as written. The drug didn't replace diet, movement, and sleep — it was layered on top of them. The teens in the treatment arm weren't sitting still while a pen did the work. They were running the lifestyle program and taking the medication. The medication is an adjunct. A powerful one, given the size of the gap — but an adjunct.

That's not a disclaimer tacked on for politeness. It's how the result was built. A family that pictures the injection as a swap for the hard, unglamorous parts — the cooking, the schedule, the protein, the sleep a 15-year-old never quite gets — has misread the trial. STEP TEENS never tested that scenario. It tested the drug on top of a foundation, and the foundation was there for everyone in the study, on both sides of the placebo line.

For most families, that reframes the whole question. It stops being "drug or no drug." It becomes "we're building the foundation either way — does adding the medication make sense for this specific kid, in this specific situation?"

The safety signals you should know

Side effects belong in this conversation, not as a footnote, and STEP TEENS reported them plainly.

The most common were gastrointestinal, which is the GLP-1 story across the board — nausea, vomiting, diarrhea, abdominal pain, and constipation. GI events showed up in 62% of the semaglutide group against 42% on placebo. They tend to cluster early and ease as the dose climbs slowly, but they're common and real.

Two safety items deserve a closer look.

Gallstones. Cholelithiasis — gallstones — occurred in 5 participants (4%) in the semaglutide group and none in the placebo group. Rapid weight loss from any cause raises gallstone risk, and that signal showed up here. It's not a reason to panic, but it's a reason to know the symptoms (sharp pain in the upper-right abdomen, especially after a fatty meal) and to flag them to the care team if they appear.

Serious adverse events. These were reported in 11% (15 of 133) on semaglutide and 9% (6 of 67) on placebo — close to each other, which is reassuring within the window of the trial.

Beyond the trial itself, the broader semaglutide label carries warnings every family should hear out loud. The most common reactions are gastrointestinal — nausea, vomiting, diarrhea, abdominal pain, and constipation. And there's a hard line worth stating plainly: semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The label carries a boxed warning about thyroid C-cell tumors. That's an absolute no, not a "weigh the pros and cons" — which is why family medical history comes up before a prescription, not after.

Acute pancreatitis is a separate, less common concern that has been reported; if it's suspected, the drug is stopped promptly. That's the kind of thing a specialist monitors for, and another reason this isn't a self-managed situation.

The two ends of the safety picture look nothing alike. GI side effects are common, usually manageable, and tend to fade. The MTC/MEN 2 contraindication is rare to run into but absolute when it applies. Part of a specialist's job is sorting out which of those conversations your family is even having.

The caveat that outweighs any single row of that table isn't in the table at all. It's time. STEP TEENS ran 68 weeks. The long-term safety of GLP-1 medications in adolescents — across the years a teenager is still growing and developing — hasn't been established yet, for the plain reason that the long-term studies haven't had time to run. That's not a knock on the drug. It's where the evidence stands right now, and a careful family deserves to hear it said rather than glossed.

Approval status: Wegovy at 12 and up

A point of precision that confuses a lot of parents. For adolescent obesity, the relevant brand is Wegovy — semaglutide at the 2.4 mg dose. The US FDA approved Wegovy for adolescents 12 and older with obesity in December 2022, on the strength of STEP TEENS.

Ozempic is the same molecule (semaglutide) at doses used for type 2 diabetes — a different product for a different purpose, and not the adolescent-obesity option. So when an article puts "Ozempic" and "teen weight loss" in the same breath, that's a tell that it's loose with the details. Here, the on-label adolescent product is Wegovy.

Approval status also varies by country, and an FDA decision doesn't automatically mean a medicine is approved or available for adolescents where you live. That's a question for a local specialist who knows your country's regulatory picture, not something to assume from a US headline.

What a parent can do with this

You're not meant to make this call alone, and you're certainly not meant to source anything yourself. This is a medication decision made and supervised by a pediatric obesity or endocrine specialist. What you can do is walk into that conversation as a useful partner rather than a passenger — here's how.

Start with the right door. The first step isn't a prescription, it's an evaluation. Pediatric obesity care is a specialty. A good assessment looks at your child's growth pattern, overall health, family history, mental and emotional wellbeing, and whether a medication is even part of the picture for them. Many kids who'd benefit from structured lifestyle support don't need a drug at all.

Build the foundation either way. Sleep, movement they genuinely enjoy, and a food environment that isn't a daily battle — none of that is wasted effort, with or without medication. STEP TEENS was built on exactly this foundation, for every participant. It's the floor the whole conversation stands on.

Bring the questions, not the conclusions. Walk in curious, not decided. You don't need to arrive having chosen yes or no. You need a specialist who'll look at your specific kid and tell you what the evidence does and doesn't say for them.

Protect the kid in the room. This is a sensitive subject for a teenager, and how it's framed at home matters. The goal is health and how they feel day to day — not a number, not a comparison, and definitely not anything that lands as shame. The clinical conversation can happen without your child ever feeling like a problem to be fixed.

Questions worth bringing to the specialist

Walk in with these and the visit gets more useful, fast.

1. "Does my child meet the criteria the trial studied?" STEP TEENS was specifically adolescents with obesity at or above the 95th BMI percentile. The first question is whether your kid is in that group at all — and that's a clinical judgment, not a guess.

2. "What does the lifestyle plan look like, with or without medication?" Since the drug was only ever tested as an add-on to lifestyle support, that support is part of any real plan. Ask what it concretely involves.

3. "What's our family history with thyroid cancer or MEN 2?" This one is non-negotiable to get on the table before anything starts, because of the boxed warning. If you don't know, it's worth finding out.

4. "How would we handle the GI side effects, and what gallbladder symptoms should we watch for?" GI effects hit most kids early; gallstones are rarer but real. Knowing the plan and the warning signs in advance beats improvising later.

5. "What do we really know about the long-term picture, and what don't we?" A specialist who's straight with you about the 68-week evidence window — and honest that the multi-year data in adolescents isn't in yet — is a specialist worth trusting.

6. "If we start, how is this monitored, and what would make us stop?" This is ongoing, supervised care with check-ins, not a one-time decision. Knowing the off-ramps up front is part of doing it well.

Where this leaves you

STEP TEENS is a serious piece of evidence, and it's worth treating as one. In adolescents with obesity, semaglutide 2.4 mg plus lifestyle support lowered BMI by 16.1% over 68 weeks, while the placebo-plus-lifestyle group barely moved — a 16.7-percentage-point gap that's hard to wave away. Parents deserve to hear that number without it being either oversold or shrugged off.

And the frame around it carries equal weight: this was tested in teens with obesity specifically, on top of a lifestyle foundation, with gastrointestinal side effects in the majority, a small gallstone signal, and a long-term safety picture in adolescents that's still being written. A powerful tool inside a defined set of conditions — not a shortcut, and not a call to make from a phone screen at 11 p.m.

So if your teen might fit the picture this trial drew, the next move isn't to go looking for a pen. It's to book an evaluation with a pediatric obesity or endocrine specialist, bring the questions above, and let someone who can examine your specific child tell you what the evidence means for them. That's not a brush-off. It's the one version of this that's genuinely safe — and the one the science backs.

This is general information drawn from published clinical trials and peer-reviewed research, not medical advice for your child. Decisions about prescribing or using any medication in an adolescent should be made with a qualified pediatric specialist who can evaluate your child directly.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app